معرفی
Daniel Bauer is a faculty member at Boston Children's Hospital and Dana-Farber Cancer and Blood Disorders Center, affiliated with Harvard Medical School in the Department of Hematology and Oncology. His research is centered on developing gene-editing therapies for blood disorders, particularly sickle cell disease and thalassemia.
- University: Boston Children's Hospital
- School: Harvard Medical School
- Department: Department of Hematology and Oncology
Dr. Bauer’s research focuses on leveraging CRISPR and base editing technologies to reactivate fetal hemoglobin and correct genetic defects in hematopoietic stem cells. His work spans from mechanistic studies of hemoglobin switching regulators like BCL11A to translational applications in non-human primates and human cells. He has pioneered methods to improve editing efficiency, reduce genotoxicity, and develop safer delivery systems.
His recent publications highlight a strong trend in refining gene-editing tools for clinical use—emphasizing in vivo delivery, off-target assessment, prime editing optimization, and culture-free editing to preserve stem cell function. These studies demonstrate a clear trajectory toward curative therapies for hemoglobinopathies.
Dr. Bauer has mentored trainees and led a productive research program, though specific student names and awards are not listed in the provided text. He has secured research funding to support his lab’s work in genome editing and therapeutic development.
He leads a research team focused on genetic medicine for blood disorders, integrating molecular biology, genomics, and preclinical models to advance gene therapy. His lab is actively involved in both basic and translational research, aiming to bridge the gap between bench discoveries and clinical applications.
